Home/ Stocks/ MIRM

Mirum Pharmaceuticals, Inc. Common Stock

MIRM XNAS

$107.16 +4.23 (+4.11%) ▲ 15-min delayed

Open

$103.93

High

$109.60

Low

$103.76

Volume

1.79M

Market Cap

$6.53B

About Mirum Pharmaceuticals, Inc. Common Stock

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 372 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$159.88M	$-790,155,000	$-13.43
FY 2025	$521.31M	$-23,363,000	$-0.47
Q3 2025	$133.01M	$2.90M	$0.06
Q2 2025	$127.78M	$-5,861,000	$-0.12

Earnings & Analyst Ratings

Next Earnings: Tue, Aug 4, 2026

Calendar →

Related Market News

No specific coverage for MIRM yet. Check out our latest market news or earnings calendar.

Get MIRM Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Mirum Pharmaceuticals, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.